Kathmere Capital Management LLC Grows Stock Holdings in Cencora, Inc. (NYSE:COR)

Kathmere Capital Management LLC lifted its holdings in Cencora, Inc. (NYSE:COR) by 15.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,498 shares of the company’s stock after acquiring an additional 198 shares during the quarter. Kathmere Capital Management LLC’s holdings in Cencora were worth $364,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cairn Investment Group Inc. purchased a new position in shares of Cencora during the 1st quarter valued at about $2,294,000. NBC Securities Inc. purchased a new position in Cencora during the first quarter valued at approximately $976,000. Park Avenue Securities LLC purchased a new position in Cencora during the first quarter valued at approximately $2,114,000. Vanguard Group Inc. purchased a new stake in Cencora in the 4th quarter worth approximately $4,212,508,000. Finally, Cullen Investment Group LTD. acquired a new stake in shares of Cencora during the 1st quarter worth approximately $924,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Stock Performance

Shares of NYSE:COR opened at $225.30 on Friday. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53. Cencora, Inc. has a 1 year low of $171.65 and a 1 year high of $246.75. The firm has a market capitalization of $44.94 billion, a PE ratio of 24.65, a P/E/G ratio of 1.58 and a beta of 0.48. The business’s 50 day moving average price is $229.12 and its 200-day moving average price is $227.99.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.65 by $0.15. The company had revenue of $68.41 billion for the quarter, compared to analysts’ expectations of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The firm’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the company posted $3.50 EPS. As a group, equities research analysts expect that Cencora, Inc. will post 13.44 earnings per share for the current fiscal year.

Cencora Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, May 24th. Shareholders of record on Friday, May 10th were paid a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date of this dividend was Thursday, May 9th. Cencora’s dividend payout ratio (DPR) is presently 22.32%.

Analysts Set New Price Targets

A number of analysts recently issued reports on the stock. Robert W. Baird increased their price target on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. SVB Leerink restated an “outperform” rating and issued a $275.00 price target on shares of Cencora in a research note on Thursday. Finally, Citigroup increased their price target on Cencora from $265.00 to $280.00 and gave the stock a “buy” rating in a research report on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $235.30.

Insider Transactions at Cencora

In other Cencora news, EVP Gina Clark sold 1,874 shares of the business’s stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $223.86, for a total value of $419,513.64. Following the transaction, the executive vice president now directly owns 13,284 shares in the company, valued at approximately $2,973,756.24. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $235.09, for a total value of $13,532,720.76. Following the sale, the chief operating officer now directly owns 24,412 shares in the company, valued at approximately $5,739,017.08. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Gina Clark sold 1,874 shares of the stock in a transaction dated Friday, May 31st. The stock was sold at an average price of $223.86, for a total transaction of $419,513.64. Following the transaction, the executive vice president now directly owns 13,284 shares of the company’s stock, valued at approximately $2,973,756.24. The disclosure for this sale can be found here. Insiders have sold a total of 1,956,675 shares of company stock worth $422,352,056 in the last quarter. Company insiders own 15.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.